Results 171 to 180 of about 138,518 (265)

Complete genome sequences of nine double recombinant vaccine-derived novel oral poliovirus type 2 genomes from Nigeria 2023-2024. [PDF]

Microbiol Resour Announc
Castro CJ, Oderinde BS, Poston KD, Mawashi KY, Bullard K, Akinola M, Meade C, Liu H, Hu F, Bullows JE, Gonzalez Z, Pang H, Sarris S, Agha C, Dybdahl-Sissoko N, Perry DB, McDuffie L, Henderson E, Burns CC, Jorba J, Baba M.   +20 more
europepmc   +1 more source

Gene Editing for Haemophilia—The Next Frontier

Haemophilia, EarlyView.
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti, Gregory A. Newby, Sundar Selvaraj, Steven W. Pipe   +3 more
wiley   +1 more source

Mucosal immunization with the lung Lactobacillus-derived amphiphilic exopolysaccharide adjuvanted recombinant vaccine improved protection against P. aeruginosa infection. [PDF]

PLoS Pathog
Zhang H, Sheng S, Li C, Bao X, Zhao L, Chen J, Guan P, Li X, Pan N, Liang Y, Wang X, Sun J, Wang X.   +12 more
europepmc   +1 more source

Real‐World Outcomes of Prophylaxis With rIX‐FP in Germany: A Prospective, Non‐Interventional Study in Haemophilia B

Haemophilia, EarlyView.
ABSTRACT Introduction Efficacy and safety of albutrepenonacog alfa (rIX‐FP) in people with haemophilia B (PwHB) has been previously demonstrated in clinical trials. However, real‐world data insights are required. Aim To describe real‐world effectiveness and tolerability of rIX‐FP in PwHB in Germany.
Johannes Oldenburg, Swee Wenning, Susanne Holzhauer, Wolfgang Miesbach, Robert Klamroth, Thomas Linhoff, Patrick Sommerer, Christian Pfrepper, Martin Olivieri, all study investigators   +9 more
wiley   +1 more source

A Modified Variant of <i>Fasciola hepatica</i> FhSAP-2 (mFhSAP-2) as a Recombinant Vaccine Candidate Induces High-Avidity IgG2c Antibodies and Enhances T Cell Activation in C57BL/6 Mice. [PDF]

Vaccines (Basel)
Ramos-Nieves R, Armina-Rodriguez A, Figueroa-Gispert MDM, Figueroa-Quiñones G, Ocasio-Malavé C, Espino AM.   +5 more
europepmc   +1 more source

BLIMP‐1 and CD39 expression define human effector memory regulatory T cells in blood and recall responses to viruses

Immunology &Cell Biology, EarlyView.
This study found that BLIMP‐1 is highly expressed in activated effector/memory human regulatory T cells, especially CD39+ Tregs, where it is associated with increased IL‐10 production and a conserved phenotype across blood and lung tissues during immune responses such as SARS‐CoV‐2 infection.
Chansavath Phetsouphanh, Laura Cook, Katherine J. L. Jackson, Deirdre Cuff, Vera Klemm, Bikash Manandhar, Denise C. Hsu, Yin Xu, John J. Zaunders, Anthony D. Kelleher, Nabila Seddiki   +10 more
wiley   +1 more source

Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac®) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled study. [PDF]

Hum Vaccin Immunother
Nency YM, Sekartini R, Wirahmadi A, Maria S, Farhanah N, Hapsari R, Mahati E, Maharani N, Mulyono M, Anantyo DT, Pramudo SG, Yeremia GF, Setyaningsih L, Puspita M, Sari RM.   +14 more
europepmc   +1 more source

Immunometabolic Modulation by Low‐Dose Sodium Butyrate: PI3K/Akt/mTOR Signalling Orchestrates Macrophage Polarization to Protect Against Clostridioides difficile Colitis

Immunology, EarlyView.
Clostridioides difficile toxins TcdA and TcdB enter intestinal epithelial cells (IECs) via specific receptors, disrupt tight‐junction integrity and activate PI3K/Akt/mTOR signalling, promoting inflammasome assembly and IL‐1β release. Toxin‐induced IEC apoptosis further weakens the epithelial barrier.
Sisi Zhang, Zhou Jingxiang, Caixia Tan, Yuanyuan Xiao, Ju Zou, Biyue Tian, Anhua Wu, Chunhui Li   +7 more
wiley   +1 more source